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trials have shown a definitive benefit over tamoxifen 
in terms of disease-free survival (d f s), benefit in terms 
of overall survival (o s) is less clear. Early trials of 
tamoxifen often used o s  as the primary endpoint, but 
recent trials comparing the a is with tamoxifen have 
used other endpoints in addition to o s  to demonstrate 
clinical benefit, and so it is important to review the 
endpoints in the context of current clinical care of 
postmenopausal women with breast cancer.
2.  TRIAL ENDPOINTS
2.1  What Are the Clinically Meaningful Endpoints 
in Trials of Adjuvant Endocrine Therapy?
Clinically meaningful endpoints are distinct measure-
ments or analyses that reflect how a patient feels, 
functions, or survives 2. Survival benefits are con-
sidered the ideal primary efficacy endpoints by the 
U.S. Food and Drug Administration (f d a ) 3 and thus 
improvement in o s  has long been considered the “gold 
standard” for evaluating the efficacy of cancer drugs 
in phase iii clinical trials in the adjuvant setting.
Although o s  is the most objective measure of ef-
ficacy, its evaluation requires prolonged follow-up, 
and consequently, the use of surrogate endpoints has 
become acceptable. In addition, o s  measurements are 
affected by the development of effective salvage treat-
ments for patients with metastatic disease, and they 
therefore may not be a pure efficacy endpoint in the 
evaluation of adjuvant therapy. The most widely used 
surrogate endpoints in oncology are d f s  or event-free 
survival, the latter being the time from the beginning 
of treatment until a patient experiences a recurrence, 
a new primary cancer, or death. For some cancers, 
d f s  is now recognized as an acceptable endpoint for 
evaluating therapies 4. Another endpoint whose im-
portance is also recognized is relapse-free survival 
or recurrence-free survival (r f s), which is the time 
from the start of treatment until a recurrence of the 
original cancer. Time to distant recurrence (t t d r), 
which, as the term implies, does not include local 
or regional recurrence, therefore depends on distant 
events. With breast cancer, distant events in patients 
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1.  INTRODUCTION
The efficacy of tamoxifen as adjuvant therapy for 
women with estrogen receptor (e r)–positive early 
breast cancer has been clearly demonstrated. Adjuvant 
tamoxifen treatment has been associated with a 31% 
reduction in the annual breast cancer mortality rate 
among hormone receptor–positive women with early 
breast cancer 1, initially making it a standard of care 
for this patient population. However, with the advent 
of the aromatase inhibitors (a is)—namely anastrozole, 
exemestane, and letrozole—the standard of care has 
been evolving. The efficacy of the a is in comparison 
with tamoxifen has been examined in recently com-
pleted or ongoing trials, and although data from these VERMA et al.
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on adjuvant therapy have been observed to be more 
frequent within the first 2–3 years following surgery 
and to be associated with poorer survival 5.
Early trials of tamoxifen for the adjuvant treatment 
of breast cancer used o s  and d f s  as primary efficacy 
endpoints. However, these early trials were compar-
ing tamoxifen with placebo, rather than with an active 
drug. The more recent a i trials have used d f s  as the 
primary endpoint, with t t d r  and r f s as surrogate end-
points of clinical benefit (Table i). Although very early 
trials of tamoxifen did not include contralateral breast 
cancer (c l b c) in estimations of d f s  7, c l b c  is now com-
monly accepted and taken into account when evaluat-
ing d f s  as a primary endpoint. However, confusion 
arises from the fact that the definition of c l b c  in itself 
varies between studies, with some studies including 
ductal and lobular cancer in situ (d c i s  and l c i s) within 
c l b c  and others not 14. Furthermore, evaluation of 
second primary cancers may include or exclude c l b c. 
As well, in some recent studies, secondary endpoints 
such as time to recurrence (t t r) and r f s have varied 
with respect to inclusion of c l b c. For example, in the 
Arimidex, Tamoxifen, Alone or in Combination 
(a t a c) study comparing anastrozole with tamoxifen 15, 
t t r included new contralateral tumours; but in the 
Breast International Group (b i g) 1-98 study comparing 
letrozole with tamoxifen 13, r f s did not include c l b c. 
These inconsistencies in trial methodology can make 
a comparison of data from different trials difficult, 
particularly if the absolute benefit is small.
2.2  How Does DFS Correlate with OS?
The use of d f s  as a surrogate endpoint for o s  is most 
appropriate in settings in which recurrence of the 
disease is responsible for a major component of 
mortality in the treated population, which is the case 
for most solid tumours 16. According to the 2007 f d a  
guidance document on clinical trial endpoints for the 
approval of cancer drugs and biologics, “d f s  can be 
an important endpoint in situations where survival 
may be prolonged, making a survival endpoint im-
practical” 3. The primary basis of f d a  approval for 
adjuvant hormonal and cytotoxic therapies for breast 
cancer and for adjuvant therapy for colon cancer has 
been d f s .
With respect to early breast cancer, o s  alone was 
often used as the primary endpoint in early trials of 
adjuvant therapy. However, in interim analyses of 
some studies, it became evident that o s  benefit would 
not be apparent and that other measures such as d f s  
also had to be considered. For example, in the Na-
tional Surgical Adjuvant Breast and Bowel Project 
(n s a b p) B-14 randomized trial involving 2644 e r-
positive node-negative women, no significant ad-
vantage in o s  was found after 4 years of follow-up 
(93% and 92% for tamoxifen and placebo respec-
tively, p = 0.3); however, d f s  was 83% and 77% 
respectively (p < 0.00001) in the two cohorts 6. Con-
sequently, d f s  was used as an endpoint and has been 
found to be an adequate surrogate for o s . In a 2007 
meta-analysis of 10 randomized clinical trials of a is 
versus tamoxifen, a strong correlation between d f s  
and o s  was found 17, supporting the use of d f s  as a 
surrogate endpoint for o s  in breast cancer adjuvant 
endocrine trials. Further support was demonstrated 
in a recent analysis of 128 breast cancer adjuvant 
trials in which the difference in 2-year d f s  was found 
to be a significant predictor of the difference in 
5-year o s  18.
t a b l e  i  Endpoints used in clinical trials for adjuvant hormone treatments for early breast cancer
Reference Investigators
or study group
Pts
(n)
Study description Primary
endpoints
Fisher et al., 1989 6 n s a b p  B14 2,644 Tamoxifen vs. placebo o s , d f s
e b c t c g  1992 7 e b c t c g 29,892 Tamoxifen vs. no treatment meta-analysis o s , d f s
(40 trials) (c l b c  not included
within d f s  definition)
e b c t c g  1998 8 e b c t c g 36,689 Tamoxifen vs. no treatment meta-analysis o s , d f s
(55 trials)
Baum et al., 2002 9 a t a c 9,366 Tamoxifen vs. anastrozole d f s
Goss et al., 2003 10 m a .17 5,187 Tamoxifen followed by letrozole (extended) d f s
Coombes et al., 2004 11 i e s 4,742 Tamoxifen followed by exemestane (switch) d f s
Boccardo et al., 2005 12 i t a 448 Tamoxifen followed by anastrozole (switch) d f s
e b c t c g  2005 1 e b c t c g 66,000 Tamoxifen vs. no treatment meta-analysis o s , d f s
(71 trials)
Thurlimann et al., 2005 13 b i g  1-98 8,010 Tamoxifen vs. letrozole d f s
e b c t c g  = Early Breast Cancer Trialists’ Collaborative Group; o s  = overall survival; d f s  = disease-free survival; c l b c  = contralateral breast 
cancer; n s a b p  = National Surgical Adjuvant Breast and Bowel Project; a t a c  = Arimidex, Tamoxifen, Alone or in Combination; b i g  = Breast 
International Group; i e s = Intergroup Exemestane Study; i t a  = Italian Tamoxifen Anastrozole trial.ENDOCRINE THERAPIES IN HR+ EARLY BREAST CANCER
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It is also becoming evident that, as the length of 
follow-up increases, competing causes of death con-
found survival findings. Recent data on node-negative 
e r-positive early breast cancer treated with adjuvant 
tamoxifen at a median follow-up of 64 months showed 
that affected women had a considerably higher risk of 
dying from causes unrelated to breast cancer (10-year 
probability of all-cause mortality was 24% and of 
breast cancer mortality was 4%) 19. In the 100-month 
analysis of the a t a c  trial, a difference in o s  and an 
increasing number of deaths from other causes were 
noted in both groups 15,20, perhaps associated with the 
fact that, on additional follow-up, the average age of 
the patients enrolled in the trial is now 72 years. On 
the other hand, significant advantages in d f s , c l b c , 
and t t r were observed in the anastrozole group, as 
was a 16% lower risk of distant recurrence 20. Simi-
larly, at a 51-month evaluation of letrozole versus 
tamoxifen, patients randomly assigned to letrozole 
were 18% less likely to have a d f s  event and were 
also significantly less likely to experience distant 
metastasis 21. Thus, although o s  is the ideal standard 
endpoint that fully reflects the effects of a particular 
therapy, d f s  is not only an acceptable substitute, but 
also allows for a more efficient means to evaluate 
efficacy. However, as the f d a  guidance document 
recognizes, critical issues include the adequacy of the 
duration of study follow-up to evaluate the durability 
of a d f s  benefit and the variety of definitions for d f s . 
In most breast cancer adjuvant trials, d f s  typically 
includes local, regional, or distant recurrence, and 
death from any cause. However, some studies include 
d c i s  and l c i s  within the definition of d f s , and others 
do not (Table ii). Consequently, a panel of experts in 
breast cancer clinical trials proposed a standardized 
definition (s t e e p), adopting the more precise term 
“invasive disease-free survival,” which would include 
ipsilateral invasive breast tumour recurrence, regional 
invasive breast cancer recurrence, distant recurrence, 
death from any cause, c l b c  (invasive), and second 
primary non-breast invasive cancer 14. Indeed, breast 
cancer-related death may be a more meaningful 
marker than death from any cause or from second 
primary non-breast cancers, and should potentially 
replace these endpoints in the definition of d f s .
3.  BASIS OF ENDOCRINE AND ADJUVANT 
ENDOCRINE THERAPY TRIALS IN 
HORMONE RECEPTOR–POSITIVE BREAST 
CANCER
Women with breast cancer may have tumours with 
receptors for hormones such as estrogen or proges-
terone. Circulating estrogen binds to its cognate 
receptor in women with e r-positive breast tumours, 
which induces cell proliferation 23; consequently, 
prevention of tumour growth is based on blocking 
this interaction. A woman’s ovaries produce estrogen 
until menopause, after which smaller amounts are 
produced in peripheral tissues through conversion 
of testosterone and androgen precursors (andros-
tenedione and dehydroandrosterone) produced by the 
adrenal gland 24. This conversion occurs through the 
action of the cytochrome P450 enzyme, aromatase, 
or CYP19 25. Tamoxifen acts by blocking estrogen 
receptors on tumour cells, but the a i s block the ability 
of the aromatase enzyme to produce estrogen 26. Anas-
trozole and letrozole are nonsteroidal agents that bind 
reversibly to the aromatase enzyme; exemestane is a 
steroidal agent that binds irreversibly to aromatase 25. 
Both types of a i  reduce estrogen to less than 10% of 
the level before treatment commenced 25. Because of 
their profound estrogen depletion effect, the a i s are 
increasingly being shown to be more effective in re-
ducing recurrences, and because they do not have the 
estrogen agonist properties of tamoxifen on uterine 
tissue and the coagulation cascade, they have a dif-
ferent and better safety profile than that of tamoxifen. 
Current data support the use of a i s in the adjuvant 
setting, and treatment guidelines and consensus docu-
ments are evolving toward incorporation of a i s for the 
treatment of early-stage breast cancer 27–30.
The risk of breast cancer recurrence is highest 
within the first 5 years of primary chemotherapy 31, 
and even with tamoxifen treatment, 50% of women 
who experience a recurrence do so within the first 5 years 
t a b l e  ii  Definitions of disease-free survival in breast cancer trials 14
Referencea Investigators l r d m Death Invasive Second i/C i/C
or study group (any cause) C l b C primary d C i S l C i S
Baum et al., 2002 9 a t a c X X X X
Goss et al., 2003 10 m a .17 X X X X X
Coombes et al., 2004 11 i e s X X X X
Jakesz et al., 2005 22 a r n o X X X
Thurlimann et al., 2005 13 b i g  1-98 X X X X X
a   Subsection 1.4 provides trial details.
l r = locoregional recurrence; d m  = distant metastases; c l b c  = contralateral breast cancer; i/c = ipsilateral or contralateral; d c i s  = ductal car-
cinoma in situ; l c i s  = lobular carcinoma in situ; a t a c  = Arimidex, Tamoxifen, Alone or in Combination; b i g  = Breast International Group; 
i e s = Intergroup Exemestane Study; a r n o  = Arimidex–Nolvadex trial.VERMA et al.
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following surgery 1. Furthermore, recurrence—in 
particular, distant recurrence—is associated with 
increased mortality 32. In a retrospective study of 
1616 patients with early breast cancer, the survival 
probability for women with distant recurrence was 
41% compared with 92% for those with no recur-
rence 32. Therefore, reducing the risk of recurrence 
is of prime importance in the quest for improved 
survival. Trials with the a is have shown lower rates 
of recurrence than are seen with tamoxifen, and the 
decline is evident within 2 years of therapy start 15.
4.  UPDATES FROM ADJUVANT ENDOCRINE 
THERAPY TRIALS
Several trials with a i s for adjuvant endocrine treat-
ment in postmenopausal women with early-stage 
breast cancer are either underway or have been com-
pleted. In addition to trials for upfront a i  treatment, 
there have also been trials to evaluate switching from 
tamoxifen to an a i , or extending treatment with an a i  
after tamoxifen for 5 years (see Buzdar et al. 33 for a 
recent review). The reported d f s  benefit in these trials 
is shown in Table iii.
4.1  Upfront Trials
A recent meta-analysis carried out by the Early Breast 
Cancer Trialists Group (e b c t g ) of a number of a i  trials 
showed that, with a i s, breast cancer recurrences are 
significantly less frequent than they are with tamox-
ifen 40. The analysis focused on e r-positive women, 
and the endpoints were all breast cancer recurrences, 
including local, distant, and contralateral, and death. 
At 5 years, a i  therapy was associated with an absolute 
2.7% reduction in breast cancer recurrence and an 
absolute 1.6% decrease in breast cancer mortality 40. 
The two major upfront trials carried out so far were 
the a t a c  trial, a phase iii double-blind trial compar-
ing anastrozole and tamoxifen either alone or in 
combination for more than 5 years 9,41, and the b i g  
1-98/International Breast Cancer Study Group (i b c s g ) 
18-98 study, a double-blind phase iii trial comparing 
letrozole or tamoxifen alone or tamoxifen followed 
by letrozole and vice versa 13.
The a t a c  trial enrolled 9366 women from 21 
countries, including 635 from Canada, all of whom 
were postmenopausal with early-stage breast can-
cer 9,41,42, and all of whom had completed surgery, 
plus radiation and chemotherapy (where given). The 
women were randomly assigned to receive either 
1 mg anastrozole alone (n = 3125), 20 mg tamox-
ifen alone (n = 3116), or a combination of the two 
(n = 3125). After the first analysis at 33 months, the 
combination arm was dropped when no benefit was 
demonstrated as compared with tamoxifen alone 43. 
After a follow-up of 68 months, women with hormone 
receptor–positive disease on anastrozole showed an 
improvement in d f s  [hazard ratio (h r): 0.83; 95% 
confidence interval (c i): 0.73 to 0.94; p = 0.005], 
an improvement in t t r (h r: 0.74; 95% c i: 0.64 to 
0.87; p = 0.002), and a reduced occurrence of c l b c  
(53% reduction; 95% c i: 25% to 71%; p = 0.001) as 
compared with women on tamoxifen 41. Further, 
fewer serious side effects such as endometrial can-
cer, thromboembolic events, vaginal bleeding, and 
hot flushes were observed. Bone fractures and joint 
pain were more common in the anastrozole group, 
although the incidence of hip fracture was low and 
similar in both groups 41.
t a b l e  iii  Disease-free survival in trials of aromatase inhibitors
Strategy Reference Trial Protocol Follow-up Risk reduction (%)
(months) Relative Absolute
Upfront Forbes et al., 2008 15 a t a c Anastrozole vs. tamoxifen 100 15 4.1
Mouridsen, 2008a b i g  1-98 Letrozole vs. tamoxifen 76 12 2.3
Switch Coombes et al., 2004 11 i e s Tamoxifen to exemestane vs. tamoxifen 55.7 32 4.7
Boccardo et al., 2006 34 i t a Tamoxifen to anastrozole vs. tamoxifen 64 37.5 10.5
Jonat et al., 2006 35 a b c s g  8/a r n o  95/i t a Tamoxifen to anastrozole vs. tamoxifen 30 37.6 3.7
Kaufmann et al., 2006 36
Kaufmann et al., 2007 37 a r n o  95 Tamoxifen to anastrozole vs. tamoxifen 30.1 34 4.2
Extended Goss et al., 2003 10 m a .17 Tamoxifen to letrozole 30 42 4.6
vs. tamoxifen to placebo
Jakesz et al., 2005 38 a b c s g  6a Tamoxifen to anastrozole
Jakesz et al., 2007 39 vs. tamoxifen to placebo 62.3 38 4.7
a     Mouridsen HT. Letrozole monotherapy vs. tamoxifen monotherapy or vs. letrozole in sequence with tamoxifen for post-menopausal 
women with endocrine-responsive early breast cancer. Presented at the San Antonio Breast Cancer Symposium 2008; San Antonio, TX; 
December 10–14, 2008. 
a t a c  = Arimidex, Tamoxifen, Alone or in Combination; b i g  = Breast International Group; i t a  = Italian Tamoxifen Anastrozole trial; a b c s g  = 
Austrian Breast and Colorectal Cancer Study Group; a r n o  = Arimidex–Nolvadex trial; i e s = Intergroup Exemestane Study.ENDOCRINE THERAPIES IN HR+ EARLY BREAST CANCER
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Follow-up of the a t a c  trial beyond 5 years of 
treatment and data obtained at 100 months showed 
significant improvement in d f s , t t r, t t d r, and c l b c  
in women on anastrozole, although no difference 
in o s  was noted 14. The lower recurrence rate with 
anastrozole was maintained after treatment was com-
pleted, in particular for the hormone receptor–positive 
group, in whom the absolute benefit of 2.8% at 5 
years increased to 4.8% at 9 years (p = 0.0001). That 
finding suggests a carryover effect for anastrozole, 
whereby women continue to benefit from treatment 
with anastrozole after stopping treatment. Although 
fracture rates overall were higher in women on anas-
trozole during the treatment period, the incidence was 
the same for both groups after treatment had been 
completed 15. These long-term data from the a t a c  trial 
indicate a continued benefit with anastrozole even 
after treatment has been terminated, without further 
treatment-related side effects.
The b i g  1-98/i b c s g  18-98 study enrolled 8010 
hormone receptor–positive postmenopausal women 
worldwide, including 20 from Canada 13,42. Women 
were randomly assigned to 2.5 mg letrozole or 20 mg 
tamoxifen alone (1835 patients) or to tamoxifen for 
2 years followed by letrozole and vice versa (6193 
patients). The latter two arms were designed to com-
pare the efficacy of a sequence strategy with that of 
an upfront a i  strategy. At 25 months, women on letro-
zole showed an improvement in d f s  (8.8% vs. 10.7%; 
p = 0.003), defined as the time from randomization 
to the first local, regional, or distant recurrence; a new 
invasive cancer in the contralateral breast; a second, 
non-breast cancer; or death without a preceding can-
cer event 13. At a median follow-up of 51 months, 
three additional endpoints were included in the 
analysis, namely d f s  excluding second non-breast 
cancers; t t r defined as d f s , but excluding second, 
non-breast cancers; and exclusion of data from pa-
tients who died without a recurrence of breast cancer. 
Women randomly assigned to continuous therapy on 
letrozole showed an 18% reduction in the risk of an 
event (p = 0.007), and the 5-year d f s  estimates for 
letrozole and tamoxifen were 84% and 81% respec-
tively. A c l b c  occurred in 0.6% of women on letro-
zole as compared with 1.1% of women on tamoxifen, 
and a 1.2% absolute decrease in distant recurrence 
was observed among women on letrozole. Fewer 
gynecologic and thromboembolic events, but more 
bone fractures, arthralgia, and low-grade hypercho-
lesterolemia were experienced by women on letro-
zole as compared with those on tamoxifen 44.
Updated results at a median follow-up of 76 
months (reported at the 2008 San Antonio Breast 
Cancer Symposium) continued to support improved 
survival for patients treated with letrozole 45; how-
ever, the weight of evidence favouring an upfront 
a i over tamoxifen resulted in the unblinding of the 
tamoxifen arm shortly after the 51-month analysis, 
and 619 patients (25.2%) selectively crossed over to 
letrozole, mostly in years 3–5. The unblinding con-
founded the statistical analysis, and the 76-month 
comparison of upfront letrozole with tamoxifen has 
been difficult; however, letrozole has continued to 
show superior efficacy over tamoxifen (Mouridsen 
HT. Letrozole monotherapy vs. tamoxifen monother-
apy or vs. letrozole in sequence with tamoxifen for 
post-menopausal women with endocrine-responsive 
early breast cancer. Presented at the San Antonio 
Breast Cancer Symposium 2008; San Antonio, TX, 
U.S.A.; December 10–14, 2008). A trend toward an 
o s  benefit is also now evident (p = 0.08); however, 
whether this trend is real or confounded by the 
crossover of patients from tamoxifen to letrozole is 
difficult to assess 46.
The Tamoxifen Exemestane Adjuvant Multina-
tional (t e a m) study was initiated in 2001 in 9 coun-
tries to examine the efficacy of exemestane versus 
tamoxifen in 9775 hormone-sensitive women with 
early breast cancer 46. However, the study design 
was revised in 2004, and patients on tamoxifen were 
switched to exemestane after 2.5–3 years, when the 
Intergroup Exemestane Study (i e s) study (described 
in the next subsection) reported superior results for 
a switch from tamoxifen to exemestane after 2–3 
years. At 2.75 years, the event rate in both groups 
was low, but exemestane was associated with an 
improvement in d f s  46. Also, being that t e a m is an 
open-label trial, significant rates of discontinuation 
of the study drug have occurred (30% for tamoxifen, 
19% for exemestane), which may confound study 
analysis in the future.
Two key head-to-head trials of a is as adjuvant 
treatment for women with early breast cancer are 
underway. The Femara versus Anastrozole Clinical 
Evaluation (f a c e) is a phase iii, open-label, randomized, 
multicentre trial designed to test whether anastrozole 
or letrozole has superior efficacy as adjuvant treatment 
for 5 years in postmenopausal women with hormone 
receptor–positive, node-positive disease 47. The trial is 
recruiting 4000 patients from 250 international sites, 
and recurrence and survival will be assessed every 
12 months. Another phase iii trial, m a .27 from the 
National Cancer Institute of Canada (n c i c), is com-
paring anastrozole with exemestane in the treatment 
of postmenopausal women with hormone receptor-
positive disease (visit www.clinicaltrials.gov/ct/show/
NCT00066573 for details) and has completed accrual. 
Results of these trials should yield useful information 
about the individual effects and relative efficacy of 
the a is.
4.2  Switch and Sequential Trials
The Italian Tamoxifen Arimidex (i t a ) trial has been 
evaluating a switch to anastrozole after 2–3 years of 
tamoxifen 12,34. In that trial, 448 women with node-
positive, e r-positive tumours were randomly assigned 
to anastrozole or continuation on tamoxifen after 2–3 VERMA et al.
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years on tamoxifen 12. At 64 months, o s  was superior 
in those who had switched to anastrozole, but the 
difference did not reach statistical significance 34. 
However, r f s  was superior in the anastrozole group as 
compared with the group that remained on tamoxifen 
(p = 0.01). Gastrointestinal complaints, musculoskele-
tal disorders, fractures, disorders of lipid metabolism, 
and hyperglycemia were more common in women on 
anastrozole. Women on tamoxifen developed more 
venous disorders and gynecologic changes (including 
endometrial cancer). Notably, however, the trial was 
unable to fulfil the sample size calculations because 
of competing trials, and the results are therefore 
based on the patients who were able to be recruited 
to the trial.
Two additional trials, the Arimidex–Nolvadex 
(a r n o  95) study and the Austrian Breast and Col-
orectal Cancer Study Group (a b c s g ) trial 8, which 
together involve 3224 women with e r-positive early-
stage breast cancer, are also examining the effect of 
continuation on tamoxifen after 2 years, as compared 
with a switch to anastrozole for a further 3 years 22. 
At 28 months, fewer events (local or metastatic re-
currence, contralateral breast cancer, or death) were 
noted in the anastrozole group than in the tamoxifen 
group (p ≤ 0.001), representing a 40% reduction in 
the risk of an event in women switched to anastrozole 
after being on tamoxifen for 2 years. Although more 
fractures and bone pain were recorded in the anastro-
zole group, fewer thromboses occurred 22. A German 
subgroup of the a r n o  study, involving 979 patients, 
also reported improved o s  and d f s  at a median follow-
up of 30 months, with fewer adverse events reported 
in the anastrozole group 37.
A meta-analysis of the three aforementioned tri-
als confirmed that, among patients who switched to 
anastrozole as compared with those who remained 
on tamoxifen, fewer disease recurrences and deaths 
were observed, resulting in significant improvements 
in d f s  (p < 0.0001), event-free survival (p < 0.0001), 
distant recurrence-free survival (p = 0.002), and o s  
(p = 0.04) 35.
In contrast with the switch trials, in which events 
are analyzed from the point of the switch (after 2–3 
years of treatment with tamoxifen), sequential trial 
strategies analyze events from the start of treatment. 
Sequential and switch trials investigate the same in-
tervention, but they are conducted in different patient 
groups and are therefore expected to provide different 
results. The a b c s g  8 trial was recently completed, and 
the sequencing strategy continued to show improved 
benefit as compared with tamoxifen alone for 5 
years 48. However, it should be noted that the sample 
size and statistical calculations were completed after 
a r n o  and a b c s g  combined all their accrued patients. 
The results from a b c s g  alone provide a clinical clue, 
but cannot truly be interpreted as a trial result.
The i e s is a double-blind randomized trial that 
compares a switch to exemestane in postmenopausal 
women with early breast cancer who have been on ta-
moxifen for 2–3 years with continuation of tamoxifen 
alone for a total of 5 years 11. The trial enrolled 4742 
women from 37 countries who had been on tamoxifen 
for 2–3 years and who were then randomly assigned to 
either switch to exemestane or continue on tamoxifen 
for up to 5 years 11. After a median follow up of 55.7 
months, evaluation of the data showed a 24% risk 
reduction and a 3.3% absolute benefit of switching to 
exemestane. After treatment, exemestane maintained 
its d f s  advantage, which is consistent with a carryover 
effect for the tamoxifen–exemestane switch strategy 
similar to the effect seen with tamoxifen alone. The 
differences in carryover effect seen in a t a c  and i e s 
may have occurred because, during the first 2–3 years 
of treatment, tamoxifen failed to eliminate microme-
tastases that later emerged as recurrences, or because 
patients in the i e s trials received only 3 years of a i  
therapy as compared with 5 years of a i  therapy in 
a t a c . Furthermore, although an o s  benefit was seen, 
it appears that that benefit is driven by fewer non-
cancer-related deaths in the exemestane arm 49. An 
endometrial substudy determined that women who 
switched to exemestane had significant reductions 
in endometrial thickening and uterine volume as 
compared with women who remained on tamoxifen 
at 24 months post treatment 50.
The most recent analysis for the b i g  1-98/i b c s g  
18-98 trial, in addition to reporting the monotherapy 
analysis with either letrozole or tamoxifen alone, 
also included an analysis on sequencing to letrozole 
for 3 years following 2 years on tamoxifen and vice 
versa 13. Approximately 1550 women were given 
letrozole followed by tamoxifen or vice versa. At 
a median follow-up of 76 months, sequential treat-
ments did not improve d f s  as compared with upfront 
letrozole alone 45. The study was designed to assess 
superiority of the sequence arms over letrozole 
monotherapy, and based on the results, all that can 
be said is that the sequence strategy is not superior 
to an upfront a i  strategy.
The e b c t g  recently carried out a meta-analysis 
of the a b c s g  8, a r n o  95, i e s/b i g  2-97, and i t a  trials 
and showed that a i s are associated with significantly 
fewer breast cancer recurrences, even in the switch 
setting, and furthermore, a statistically significant 
improvement in mortality rates 40. However, these 
findings should be interpreted with caution given the 
significant heterogeneity of study populations in the 
switch trials.
4.3  Endocrine Extension Trials
Several trials have examined the efficacy of adju-
vant treatment extended beyond the standard 5-year 
duration. These have included extended treatment 
on tamoxifen or an a i  beyond 5 years, or sequential 
treatment with an a i  in women who were disease-free 
after 5 years on tamoxifen. The Adjuvant Tamoxifen, ENDOCRINE THERAPIES IN HR+ EARLY BREAST CANCER
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Longer Against Shorter (at l a s) randomized trial is 
comparing 10 years with 5 years of tamoxifen in 
11,500 women (59% e r-positive). A lower recurrence 
rate has been observed among women continuing on 
tamoxifen at a mean of 4.2 years following random-
ization 51. Similarly, the Adjuvant Tamoxifen—To 
Offer More (at tom) trial has randomly assigned 
6934 women in the United Kingdom who have al-
ready received 5 years of tamoxifen to cessation or 
continuation for another 5 years 52. With a median 
follow-up of 4.2 years, fewer recurrences (although 
not statistically significantly fewer: p = 0.4) were 
observed in the group on extended treatment, but the 
risk of endometrial cancer was also observed to be 
doubled. Of interest, an earlier study found no benefit 
for extended treatment with tamoxifen in women 
with node-negative cancer 53. In that study, d f s  was 
82% in patients who discontinued tamoxifen as com-
pared with 78% (p = 0.07) in those who continued 
to receive it.
The double-blind m a .17 trial from the n c i c  Clinical 
Trials Group is looking at the effect of either letrozole 
or placebo in women who have already undergone 
standard 5-year treatment with tamoxifen 10,54. Fol-
lowing approximately 5 years of tamoxifen treatment, 
m a .17 randomly assigned 5187 postmenopausal wom-
en with early-stage breast cancer to either letrozole 
or placebo. The 4-year d f s  is 94.4% and 89.8% for 
patients receiving letrozole and placebo respectively, 
representing an absolute reduction of 4.6% for patients 
on letrozole (p < 0.001) 55. After a median follow-up 
of 30 months, the trial was unblinded, and patients 
who received placebo were offered letrozole; 66% of 
patients on placebo opted to take letrozole 56. At 2.8 
years from unblinding, 2% in the letrozole group as 
compared with 4.9% in the placebo group experienced 
an event 57. These data indicate that letrozole improves 
d f s  and distant d f s , even when a substantial period 
of time has elapsed since the discontinuation of prior 
adjuvant tamoxifen.
The a b c s g  trial 6a is similar to m a .17: It is exam-
ining the efficacy of 3 years of anastrozole treatment 
in women who have completed 5 years of tamoxifen 
treatment, with or without the first-generation a i  
aminoglutethimide for the first 2 years of therapy 39. 
Disease-free patients (n = 856) were randomly as-
signed to receive either 3 years of anastrozole or 
no further treatment. At a median follow-up of 62.3 
months, women who received anastrozole (n = 387) 
had a statistically significantly reduced risk of re-
currence (locoregional recurrence, c l b c , or distant 
metastasis) as compared with women who received 
no further treatment (p = 0.031) 39.
The n s a b p  B-33 trial was designed to examine 
whether exemestane treatment (versus placebo) 
prolongs d f s  following 5 years of tamoxifen treat-
ment 58. However, following the results of the 
m a .17 extended trial with letrozole, n s a b p  B-33 was 
unblinded after 29 months, and women on placebo 
were offered exemestane. At 30 months’ median 
follow-up, women originally assigned to exemestane 
showed an improvement in 4-year d f s  and r f s  58.
4.4  Trials in Premenopausal Women
The addition of 5 years of tamoxifen in premenopausal 
women with hormone receptor–positive disease is as-
sociated with a 40% reduction in recurrence 1,8. More 
recently, drug-induced ovarian suppression has been 
examined. The Zoladex Early Breast Cancer Research 
Association trial showed that goserelin treatment was 
as effective as cyclophosphamide, methotrexate, and 
fluorouracil chemotherapy for treatment of pre- and 
perimenopausal women with node-positive, e r-posi-
tive breast cancer 59. In the Zoladex in Premenopausal 
Patients trial, premenopausal women were randomly 
assigned to goserelin alone for 2 years, tamoxifen 
alone for 2 years, goserelin plus tamoxifen for 2 years, 
or no endocrine treatment, after surgery and standard 
chemotherapy or radiotherapy, or both 60. Goserelin 
either alone or with tamoxifen was associated with a 
significant decrease in the risk of recurrence.
Treatment with a i  alone has not been recom-
mended in premenopausal women with functioning 
ovaries following chemotherapy. In these women, 
though a i s may reduce estrogen production in periph-
eral tissue to some extent, ovarian estrogen produc-
tion is maintained or increased, which may lead to 
unfavourable effects on breast cancer risk of recur-
rence 61. However, a i  treatment together with ovarian 
suppression is currently being evaluated for premeno-
pausal patients with hormone-responsive early-stage 
breast cancer. The a b c s g-12 trial is examining the 
efficacy of anastrozole or tamoxifen in combination 
with goserelin, with or without zoledronic acid, in 
premenopausal women with hormone-responsive 
early breast cancer 62, and at a median follow-up of 60 
months, no significant difference in d f s  between the 
two endocrine therapies has been observed. However, 
the addition of zoledronic acid to endocrine therapy 
resulted in a 36% improvement in d f s  (p = 0.01) at a 
median follow-up of 48 months, and fewer patients on 
that combination experienced bone metastases 63. Fur-
ther follow-up from that study, and from other similar 
trials [a z u r e  (neoadjuvant zoledronic acid to reduce 
recurrence), for example], is eagerly anticipated to 
help clarify the role of adjuvant bisphosphonates for 
patients with early-stage breast cancer.
The i b c s g  is currently conducting three trials 
in European and North American premenopausal 
women 64,65. In the ongoing Suppression of Ovarian 
Function trial, women with endocrine-responsive 
disease who remain premenopausal after surgery or 
after the completion of chemotherapy are randomly 
assigned to tamoxifen alone for 5 years as compared 
with ovarian function suppression (triptorelin or oo-
phorectomy) in combination with either tamoxifen or 
exemestane. The Tamoxifen and Exemestane study VERMA et al.
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is enrolling premenopausal women on triptorelin 
and either tamoxifen or exemestane from the start 
of their adjuvant therapy. The Premenopausal En-
docrine Responsive Chemotherapy trial is randomly 
assigning women to ovarian suppression plus either 
tamoxifen or exemestane, or ovarian suppression 
plus either tamoxifen or exemestane plus chemo-
therapy. Trials such as these should yield important 
information concerning the efficacy of a is together 
with ovarian suppression as adjuvant treatment in 
premenopausal women.
5.  OPTIMAL DURATION OF AI TREATMENT
Several trials are being conducted to determine the 
optimal duration of a i treatment for postmenopausal 
women with early breast cancer. The m a .17R trial 
was initiated in 2004 (visit cancer.gov/clinicaltrials/ 
CAN-NCIC-MA17R for details) to compare d f s  in 
subjects who receive 5 years of letrozole or pla-
cebo after having received approximately 5 years 
(4.5–6 years) of aromatase inhibitor therapy (letro-
zole, anastrozole, or exemestane), including those 
who have received 5 years of adjuvant letrozole as 
part of the m a .17 trial. In the a b c s g -16 Secondary 
Adjuvant Long-Term Study in the Arimidex trial, 
women who have been free of recurrence after 
approximately 5 years of endocrine therapy will 
receive either 2 years or 5 years of extended adju-
vant therapy with anastrozole 66. The n s a b p  B-42 
trial will determine whether prolonged adjuvant 
hormonal therapy with letrozole will improve d f s  
in postmenopausal women with hormone receptor–
positive breast cancer who have completed 5 years 
of therapy with an a i or 5 years of therapy with a 
combination of up to 3 years of tamoxifen followed 
by an a i  67.
With ongoing studies looking into the benefits 
of an additional 5 years of treatment with an a i, 
some physicians question whether patients will be 
willing to take these medications for this length of 
time. To address that concern, a survey was recently 
conducted among patients with early breast cancer 
and the physicians who treat them. Physicians were 
asked to indicate the minimum incremental benefit 
that they believed would justify 5 additional years 
of a i therapy. Most indicated that they would pre-
scribe an a i for a further 5 years only if it produced 
an additional 1%–2% benefit in o s . When patients 
with early breast cancer on an a i therapy were asked 
the same question, one third responded that they 
would continue a i therapy for a further 5 years even 
if it offered a less-than-1% incremental benefit in 
o s . These results suggest that physicians may be 
more risk-averse than are their patients; the results 
are also encouraging in that they show that most 
patients tolerate their a i medication well enough 
to consider a further 5 years of therapy for a very 
small potential benefit 68.
6.  RESISTANCE TO ENDOCRINE THERAPY 
AND FACTORS AFFECTING DRUG ACTION
Because adjuvant endocrine therapy is generally a 
long-term treatment, the development of resistance 
and other issues affecting drug efficacy must be con-
sidered because these events will have an effect on the 
benefits of treatment. Drug resistance may be intrinsic 
or acquired. Intrinsic (de novo) resistance refers to a 
lack of response at initial exposure to the drug; ac-
quired resistance develops during therapy in patients 
who are initially responsive. Host factors, treatment 
type, and the biology of the tumour can all have a role 
to play in the development of resistance.
6.1  Host Factors
Tamoxifen is converted to anti-estrogenic metabolites 
that are thought to be more potent than tamoxifen 
itself. One of the active metabolites, endoxifen, is 
produced through the action of the cytochrome P450 
enzyme CYP2D6, and women who have particular 
allelic variants of the genes encoding this enzyme 
are poor metabolizers of tamoxifen 69,70. In family 
studies, the poor-metabolizer phenotype behaves as 
an autosomal recessive trait with an incidence of be-
tween 5% and 10% in the white population of Europe 
and North America, and leads to deficient metabolism 
of more than 20 commonly prescribed drugs 71. In 
contrast, certain populations have multiple copies 
of the CYP2D6 gene and are consequently good me-
tabolizers. For example, 29% and 21% respectively 
of Ethiopians and Saudi Arabians were found to carry 
extra CYP2D6 genes, whereas 1%–2% of Swedish, 
German, Chinese, and black Zimbabwean popula-
tions had multiple copies 72,73. Poor metabolizers of 
tamoxifen (those with CYP2D6 alleles *4, *5, *10, 
*41) are at increased risk of recurrence, while those 
with high-activity variants have a more favourable 
outcome 74. However, high metabolizers experience 
more side effects and are more likely to discontinue 
treatment 75. Thus, paradoxically, the patients who 
are most likely to benefit from tamoxifen treatment 
are also the most likely to experience adverse effects 
and to discontinue treatment. In addition, there is also 
a suggestion that the h e r 2/neu oncogene encodes a 
transmembrane tyrosine kinase receptor with ex-
tensive homology to the epidermal growth factor 
receptor and that overexpression of this gene may be 
associated with tamoxifen resistance 76,77.
Because the a i s inhibit the action of aromatase, 
the degree of expression of this enzyme—and dif-
ferences in the affinity of drug binding—could have 
a bearing on drug efficacy 78. Intrinsic resistance to 
the a i s has been suggested by variations in response 
rate to anastrozole and letrozole among women with 
e r-positive tumours 79. With respect to h e r 2/neu sta-
tus and a i  efficacy, neoadjuvant letrozole has been 
found to be equally effective in h e r 2/neu–positive ENDOCRINE THERAPIES IN HR+ EARLY BREAST CANCER
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and h e r 2/neu–negative tumours 80,81. However, a 
review of receptor status in the b i g  1-98 study, based 
on a relatively small number of patients with h e r 2/
neu-positive tumours, showed that the prognosis of 
those patients was less favourable with both letrozole 
and tamoxifen therapy 82. Further investigations are 
needed to clarify the role of tamoxifen and a i s in 
h e r 2-overexpressing breast cancers, especially in the 
current clinical context with the adoption of adjuvant 
trastuzumab for these patients.
6.2  Tumour-Related Resistance
The estrogen receptor is a member of the nuclear 
receptor family of ligand-activated transcription 
factors. Upon entering a cell, estrogen binds to the 
receptor, which then undergoes conformational 
changes and binds to elements upstream of estrogen-
dependent genes and alters their transcription either 
by up- or downregulation 83. When tamoxifen binds 
to the estrogen receptor, various conformational 
changes occur, and the regulation of estrogen-depen-
dent genes changes. Thus, tamoxifen may have activ-
ity either as an agonist or an antagonist. Tamoxifen 
resistance may arise through changes in the expres-
sion of the receptor or through decreased uptake or 
increased efflux of the drug, or through changes in 
signalling pathways 83.
Acquired resistance to the a i s has been dem-
onstrated in tissue-culture cell lines in which cells 
acquire an adaptive hypersensitivity to estrogen 
through upregulation of estrogen receptors and 
increased crosstalk between various growth factor 
receptor signalling pathways 78,79. Studies in a mouse 
tumour model have confirmed this finding. Analysis 
of letrozole-resistant tumours in mice revealed that 
the transition from a responsive state to an unrespon-
sive state was associated with activation of growth 
factor receptor pathways, particularly the Her2/Raf/
m a p k  (mitogen-activated protein kinase) signalling 
pathway, and h e r 2 expression was increased whether 
the tumours were regressing or growing 84. Gene 
expression arrays performed on tumour biopsies 
in women on neoadjuvant letrozole have shown 
alterations in numerous genes upon exposure to 
letrozole, with different changes in responders and 
non-responders 70,85. However, the significance of 
this finding is not clear, and resistance likely occurs 
through a number of mechanisms. Cross-resistance 
between steroidal and nonsteroidal a i s has not been 
observed, as demonstrated by patients with metastatic 
breast cancer who responded to exemestane following 
failure on a nonsteroidal a i  86. Interestingly, growth of 
breast cancer cell lines in tissue culture is stimulated 
by androgens, and furthermore, under conditions of 
profound estrogen depletion, these cells upregulate 
steroidogenic enzymes that metabolize androgens 
to estrogen 87. This mechanism represents another 
potential avenue of resistance to a i s.
6.3  Treatment-Related Resistance
Women on tamoxifen experiencing excessive meno-
pausal symptoms such as hot flashes may be pre-
scribed a serotonin reuptake inhibitor (s r i ), and these 
agents have been shown to inhibit CYP2D6 activity. 
Venlafaxine has been found to be a weak inhibitor of 
CYP2D6; paroxetine is a potent inhibitor 88. Thus, the 
choice of s r i  for treatment is important for ensuring 
optimum tamoxifen activity.
7.  SUMMARY
Data so far have unequivocally shown that, as com-
pared with tamoxifen, the a i s offer superior benefit 
in d f s , and adjuvant a i  treatment is accepted as the 
standard of care in early breast cancer. However, 
issues for the physician include which a i  to use and 
when to start it. Further, questions such as duration of 
treatment and the optimal treatment strategy remain to 
be answered. The data so far point to a i  treatment up 
front, because the risk of recurrence is highest within 
the first 2–3 years after surgery 1. Patients who have 
already been started on tamoxifen benefit from switch-
ing to an a i  as demonstrated in the i t a , a r n o , and a b c s g  
trials, in which patients switched to anastrozole after 
2–3 years of tamoxifen showed improvement in d f s . 
Similar results were found in the i e s trial for patients 
switched to exemestane. A question that needs further 
investigation is whether, for a particular subset of pa-
tients, tamoxifen is more beneficial as initial therapy. 
The optimal duration for therapy is another issue that 
requires further investigation. The data so far indicate 
that extended therapy is probably effective, because 
letrozole and tamoxifen showed increased benefit be-
yond 5 years in the m a .17 and at l a s trials respectively. 
In the m a .17 trial, a benefit was apparent even when 
substantial time had elapsed between treatment with 
tamoxifen and subsequent treatment with letrozole. 
What is unclear at present is the optimal duration of a i  
therapy; the s a l s a trial (anastrozole) and n s a b p  B-42 
(letrozole) will help to address that question. The a t a c  
100-month analysis demonstrated a carryover effect 
of anastrozole that was greater than the effect known 
to occur with tamoxifen 15. Again, it would be use-
ful to determine how long the carryover effect lasts 
and whether extended endocrine therapy will have a 
greater effect than that seen with the known carryover 
effect alone. Tissue markers are showing promise as 
indicators of prognosis and indicators of response. The 
future of the ideal endocrine treatment approach relies 
on further research on molecular markers and gene 
expression that could yield useful information to help 
tailor endocrine therapy for individual patients.
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